3.26.1 html 130 211 1 true 40 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.diffusionpharma.com/20260331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.diffusionpharma.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.diffusionpharma.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.diffusionpharma.com/20260331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.diffusionpharma.com/20260331/role/statement-consolidated-statements-of-stockholders-equity-unaudited Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.diffusionpharma.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - The Company and Description of Business Sheet http://www.diffusionpharma.com/20260331/role/statement-note-1-the-company-and-description-of-business Note 1 - The Company and Description of Business Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Liquidity and Capital Resources Sheet http://www.diffusionpharma.com/20260331/role/statement-note-2-liquidity-and-capital-resources Note 2 - Liquidity and Capital Resources Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies Sheet http://www.diffusionpharma.com/20260331/role/statement-note-3-summary-of-significant-accounting-policies Note 3 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Fair Value of Financial Instruments Sheet http://www.diffusionpharma.com/20260331/role/statement-note-4-fair-value-of-financial-instruments Note 4 - Fair Value of Financial Instruments Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Significant Agreements and Contracts Sheet http://www.diffusionpharma.com/20260331/role/statement-note-5-significant-agreements-and-contracts Note 5 - Significant Agreements and Contracts Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Prepaid Expenses Sheet http://www.diffusionpharma.com/20260331/role/statement-note-6-prepaid-expenses Note 6 - Prepaid Expenses Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities Sheet http://www.diffusionpharma.com/20260331/role/statement-note-7-accrued-expenses-and-other-current-liabilities Note 7 - Accrued Expenses and Other Current Liabilities Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Commitments and Contingencies Sheet http://www.diffusionpharma.com/20260331/role/statement-note-8-commitments-and-contingencies Note 8 - Commitments and Contingencies Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants Sheet http://www.diffusionpharma.com/20260331/role/statement-note-9-stockholders-equity-and-common-stock-warrants Note 9 - Stockholders' Equity and Common Stock Warrants Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Stock-based Compensation Stock Sheet http://www.diffusionpharma.com/20260331/role/statement-note-10-stockbased-compensation-stock Note 10 - Stock-based Compensation Stock Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Segments Sheet http://www.diffusionpharma.com/20260331/role/statement-note-11-segments Note 11 - Segments Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Subsequent Events Sheet http://www.diffusionpharma.com/20260331/role/statement-note-12-subsequent-events Note 12 - Subsequent Events Notes 18 false false R19.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 19 false false R20.htm 995445 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.diffusionpharma.com/20260331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.diffusionpharma.com/20260331/role/statement-note-3-summary-of-significant-accounting-policies 20 false false R21.htm 995446 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-3-summary-of-significant-accounting-policies-tables Note 3 - Summary of Significant Accounting Policies (Tables) Tables http://www.diffusionpharma.com/20260331/role/statement-note-3-summary-of-significant-accounting-policies 21 false false R22.htm 995447 - Disclosure - Note 4 - Fair Value of Financial Instruments (Tables) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-4-fair-value-of-financial-instruments-tables Note 4 - Fair Value of Financial Instruments (Tables) Tables http://www.diffusionpharma.com/20260331/role/statement-note-4-fair-value-of-financial-instruments 22 false false R23.htm 995448 - Disclosure - Note 6 - Prepaid Expenses (Tables) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-6-prepaid-expenses-tables Note 6 - Prepaid Expenses (Tables) Tables http://www.diffusionpharma.com/20260331/role/statement-note-6-prepaid-expenses 23 false false R24.htm 995449 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables Note 7 - Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.diffusionpharma.com/20260331/role/statement-note-7-accrued-expenses-and-other-current-liabilities 24 false false R25.htm 995450 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants (Tables) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables Note 9 - Stockholders' Equity and Common Stock Warrants (Tables) Tables http://www.diffusionpharma.com/20260331/role/statement-note-9-stockholders-equity-and-common-stock-warrants 25 false false R26.htm 995451 - Disclosure - Note 10 - Stock-based Compensation Stock (Tables) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-10-stockbased-compensation-stock-tables Note 10 - Stock-based Compensation Stock (Tables) Tables http://www.diffusionpharma.com/20260331/role/statement-note-10-stockbased-compensation-stock 26 false false R27.htm 995452 - Disclosure - Note 11 - Segments (Tables) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-11-segments-tables Note 11 - Segments (Tables) Tables http://www.diffusionpharma.com/20260331/role/statement-note-11-segments 27 false false R28.htm 995453 - Disclosure - Note 1 - The Company and Description of Business (Details Textual) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-1-the-company-and-description-of-business-details-textual Note 1 - The Company and Description of Business (Details Textual) Details http://www.diffusionpharma.com/20260331/role/statement-note-1-the-company-and-description-of-business 28 false false R29.htm 995454 - Disclosure - Note 2 - Liquidity and Capital Resources (Details Textual) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-2-liquidity-and-capital-resources-details-textual Note 2 - Liquidity and Capital Resources (Details Textual) Details http://www.diffusionpharma.com/20260331/role/statement-note-2-liquidity-and-capital-resources 29 false false R30.htm 995455 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual Note 3 - Summary of Significant Accounting Policies (Details Textual) Details http://www.diffusionpharma.com/20260331/role/statement-note-3-summary-of-significant-accounting-policies-tables 30 false false R31.htm 995456 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details Note 3 - Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) Details 31 false false R32.htm 995457 - Disclosure - Note 4 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details Note 4 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details) Details 32 false false R33.htm 995458 - Disclosure - Note 4 - Fair Value of Financial Instruments - Marketable Securities (Details) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details Note 4 - Fair Value of Financial Instruments - Marketable Securities (Details) Details 33 false false R34.htm 995459 - Disclosure - Note 5 - Significant Agreements and Contracts (Details Textual) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-5-significant-agreements-and-contracts-details-textual Note 5 - Significant Agreements and Contracts (Details Textual) Details http://www.diffusionpharma.com/20260331/role/statement-note-5-significant-agreements-and-contracts 34 false false R35.htm 995460 - Disclosure - Note 6 - Prepaid Expenses - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details Note 6 - Prepaid Expenses - Prepaid Expenses and Other Current Assets (Details) Details 35 false false R36.htm 995461 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) Details 36 false false R37.htm 995462 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-8-commitments-and-contingencies-details-textual Note 8 - Commitments and Contingencies (Details Textual) Details http://www.diffusionpharma.com/20260331/role/statement-note-8-commitments-and-contingencies 37 false false R38.htm 995463 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants (Details Textual) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual Note 9 - Stockholders' Equity and Common Stock Warrants (Details Textual) Details http://www.diffusionpharma.com/20260331/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables 38 false false R39.htm 995464 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details Note 9 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) Details 39 false false R40.htm 995465 - Disclosure - Note 10 - Stock-based Compensation Stock (Details Textual) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-10-stockbased-compensation-stock-details-textual Note 10 - Stock-based Compensation Stock (Details Textual) Details http://www.diffusionpharma.com/20260331/role/statement-note-10-stockbased-compensation-stock-tables 40 false false R41.htm 995466 - Disclosure - Note 11 - Stock-based Compensation Stock - Stock-based Compensation Expense (Details) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details Note 11 - Stock-based Compensation Stock - Stock-based Compensation Expense (Details) Details 41 false false R42.htm 995467 - Disclosure - Note 10 - Stock-based Compensation Stock - Stock Option Activity (Details) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details Note 10 - Stock-based Compensation Stock - Stock Option Activity (Details) Details 42 false false R43.htm 995468 - Disclosure - Note 10 - Stock-based Compensation Stock - Stock Assumptions (Details) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details Note 10 - Stock-based Compensation Stock - Stock Assumptions (Details) Details 43 false false R44.htm 995469 - Disclosure - Note 11 - Segments (Details Textual) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-11-segments-details-textual Note 11 - Segments (Details Textual) Details http://www.diffusionpharma.com/20260331/role/statement-note-11-segments-tables 44 false false R45.htm 995470 - Disclosure - Note 11 - Segments - Schedule of Segment Information (Details) Sheet http://www.diffusionpharma.com/20260331/role/statement-note-11-segments-schedule-of-segment-information-details Note 11 - Segments - Schedule of Segment Information (Details) Details 45 false false All Reports Book All Reports crvo-20260331.xsd crvo-20260331_cal.xml crvo-20260331_def.xml crvo-20260331_lab.xml crvo-20260331_pre.xml crvo20260331c_10q.htm logolg.jpg http://fasb.org/us-gaap/2026 http://xbrl.sec.gov/dei/2026 http://xbrl.sec.gov/ecd/2026 true true